ArticleAnnals of medicine2025
iTr35 cells: a novel immunoregulatory subset involved in bone loss in rheumatoid arthritis and clinical implications.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Can Microneedle-Nanocarrier Platforms Deliver True Tolerogenic Immunotherapy for Psoriasis?Vaccines · 2026Review
- Letter to the editor regarding 'iTr35 cells: a novel immunoregulatory subset involved in bone loss in rheumatoid arthritis and clinical implications'.Annals of medicine · 2025Article
- Response to letter regarding iTr35 cells a novel immunoregulatory subset involved in bone loss in rheumatoid arthritis and clinical implications.Annals of medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation and progressive bone destruction. While classical regulatory T (Treg) cells are known to inhibit osteoclastogenesis, the role of non-classical subsets such as inducible IL-35-producing regulatory T cells (iTr35) in RA-related bone loss remains unexplored.
objectiveThis prospective case-control study aimed to evaluate the expression of iTr35 cells in RA patients and assess their association with bone mineral density (BMD) and serum bone turnover markers.
methodsPeripheral blood mononuclear cells (PBMCs) were collected from 34 untreated RA patients and 34 age- and sex-matched healthy controls. Flow cytometry was used to measure the frequencies of iTr35 (CD4
resultsRA patients exhibited significantly decreased frequencies of circulating iTr35 and Treg cells, along with increased Teff. iTr35 levels were strongly negatively correlated with BMD at the lumbar spine (
conclusionThese findings identify iTr35 as a novel immunoregulatory T cell subset potentially involved in protecting against bone loss in RA. This study highlights the significance of iTr35 in osteoimmune regulation and suggests its therapeutic potential in preventing skeletal damage in autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.